By Counterforce Health Team in Krystexxa (pegloticase) —

How to Get Krystexxa (Pegloticase) Covered by Humana in Illinois: Complete Prior Authorization and Appeals Guide

Answer Box: Quick Path to Krystexxa Coverage

Yes, Humana covers Krystexxa (pegloticase) in Illinois with prior authorization for chronic refractory gout. You'll need documented failure of allopurinol AND febuxostat at maximum doses for 3+ months each, plus normal G6PD test results. Submit your PA via Humana's provider portal or fax to 877-486-2621 with complete clinical documentation. If denied, you have 65 days to appeal, followed by Illinois external review within 30 days of final denial.

First step today: Confirm your G6PD test is normal and gather documentation of failed conventional therapy trials.

Table of Contents

Eligibility Requirements Checklist

Before starting your Krystexxa prior authorization, verify you meet these core requirements:

Requirement What It Means Documentation Needed
Diagnosis Chronic refractory gout with symptoms ≥3 flares in 18 months OR tophi OR chronic gouty arthritis
Failed Conventional Therapy Inadequate response to maximum doses 3+ months each: allopurinol (≤800mg/day), febuxostat (≤80mg/day)
Uric Acid Level Persistently elevated despite treatment Serum uric acid ≥6 mg/dL documented within 1 month
G6PD Test Normal enzyme levels required Negative qualitative or normal quantitative test result
Prescriber Specialist oversight required Rheumatologist prescription or consultation
Methotrexate Plan Immunomodulator co-therapy Current 15-25mg weekly OR documented contraindication
Note: G6PD deficiency is an absolute contraindication due to risk of life-threatening hemolysis. All patients must be screened before starting Krystexxa.

Step-by-Step: Fastest Path to Approval

1. Verify Coverage and Formulary Status

Who: Patient or clinic staff
Action: Call Humana at 1-800-457-4708 to confirm active coverage and formulary placement
Timeline: 5-10 minutes

2. Complete G6PD Screening

Who: Ordering physician
Action: Order G6PD enzyme test via standard blood draw
Timeline: Results in 2-3 days
Required: Normal results to proceed

3. Gather Prior Therapy Documentation

Who: Clinic staff
Documents needed:

  • Pharmacy records showing allopurinol and febuxostat trials
  • Clinical notes documenting inadequate response or intolerance
  • Serum uric acid trends during conventional therapy

4. Submit Prior Authorization Request

Who: Prescribing physician or authorized staff
Methods:

  • Online: Humana provider portal (preferred)
  • Fax: 877-486-2621
  • Phone: 1-800-555-2546 (Mon-Fri 8am-8pm ET)

Timeline: Standard review 15-30 days; expedited 72 hours if urgent

5. Include Required Clinical Documentation

Essential attachments:

  • Medical necessity letter from rheumatologist
  • G6PD test results (normal)
  • Lab reports showing persistent hyperuricemia
  • Documentation of failed conventional therapy
  • Current methotrexate regimen or contraindication rationale

6. Track Your Request

Action: Use Humana provider portal to monitor status
Follow-up: Contact if no response within stated timeframe

7. Prepare for Potential Peer-to-Peer Review

Who: Prescribing physician
When: Humana may request before issuing denial
Prep: Review clinical rationale and supporting evidence

Common Denial Reasons & How to Fix Them

Denial Reason Fix Strategy Required Documentation
Missing G6PD test Submit normal test results Lab report showing negative/normal G6PD
Insufficient conventional therapy Document maximum tolerated doses and duration Pharmacy records + clinical notes with dates/outcomes
No methotrexate plan Add co-therapy or justify contraindication Prescription for 15-25mg weekly OR clinical rationale
Prescriber not rheumatologist Obtain rheumatology consultation Specialist evaluation and recommendation
Inadequate medical necessity Strengthen clinical rationale Detailed letter citing guidelines and patient-specific factors
From our advocates: We've seen denials overturned when clinics submit comprehensive pharmacy records showing specific dates, doses, and documented inadequate response rather than just stating "failed allopurinol." The more detailed your documentation, the stronger your case.

Appeals Process for Illinois Patients

If your initial PA is denied, Illinois provides robust appeal rights with specific timelines:

Level 1: Internal Appeal with Humana

Timeline: 65 days from denial notice to file
Process: Submit written appeal via provider portal or mail
Decision timeline: 15 business days (expedited: 24 hours if urgent)
Required: Additional clinical evidence addressing denial reasons

Level 2: External Review (Illinois-Specific)

Timeline: 30 days from final internal denial (shorter than many states)
Process: Request independent review through Illinois Department of Insurance
Cost: Free to patients (insurer pays review fees)
Decision: Binding on Humana if overturned
Contact: Illinois DOI at 877-527-9431

Critical Illinois deadline: You must request external review within 30 days of receiving your final internal appeal denial. This is shorter than the 4-month window in many other states.

Counterforce Health specializes in turning insurance denials into successful appeals by analyzing denial letters, plan policies, and clinical notes to craft targeted rebuttals. Our platform identifies specific denial reasons and drafts evidence-backed appeals aligned with each payer's own criteria, helping patients and clinicians navigate complex prior authorization requirements more effectively.

Clinical Documentation Requirements

Medical Necessity Letter Components

Your rheumatologist's letter should address these key points:

Patient-Specific Factors:

  • Confirmed gout diagnosis with ICD-10 code (M10.9 for unspecified gout)
  • Symptom severity and functional impact
  • Specific serum uric acid levels and dates
  • Documentation of tophi or joint damage if present

Treatment History:

  • Allopurinol trial: dose, duration, serum uric acid response, side effects
  • Febuxostat trial: dose, duration, serum uric acid response, side effects
  • Other agents tried (probenecid, lesinurad) if applicable
  • Current gout flare prophylaxis regimen

Clinical Rationale:

  • Why conventional therapy is inadequate
  • Expected benefits of Krystexxa therapy
  • Monitoring plan and safety considerations
  • Methotrexate co-therapy rationale or contraindications

Supporting Laboratory Data

  • Baseline and serial serum uric acid levels
  • G6PD enzyme test (normal results required)
  • Complete blood count and comprehensive metabolic panel
  • Inflammatory markers during active disease

Costs and Financial Assistance

Krystexxa carries substantial costs—approximately $30,000 per infusion with annual treatment costs potentially reaching $780,000. However, several assistance options exist:

Medicare Coverage

  • Part B coverage: Krystexxa administered in healthcare settings (J2507 billing code)
  • Cost-sharing: Standard 20% coinsurance after deductible
  • No copay cards: Federal regulations prohibit manufacturer copay assistance for Medicare patients

Financial Assistance Programs

  • Amgen By Your Side: Case management and navigation support (1-844-KRYSTEXXA)
  • PAF Co-Pay Relief: Income-based assistance for eligible patients
  • Medicare Extra Help: Low-income subsidy program for prescription drug costs

Illinois-Specific Resources

  • Illinois Department of Insurance: Consumer assistance at 877-527-9431
  • Illinois Attorney General Health Care Helpline: 1-877-305-5145
  • Local legal aid: May assist with complex appeals requiring additional evidence gathering

When to Escalate to Illinois Regulators

Contact Illinois regulators if you experience:

Procedural Violations:

  • Humana misses appeal deadlines
  • Denial without proper clinical review
  • Failure to provide required appeal information

Illinois Department of Insurance:

Illinois Attorney General:

  • Health Care Helpline: 1-877-305-5145
  • Services: Informal intervention with insurers, consumer protection

For complex cases requiring extensive evidence gathering, Counterforce Health can help analyze your denial letter and plan policies to identify specific appeal strategies tailored to Humana's requirements and Illinois regulations.

Frequently Asked Questions

Q: How long does Humana's prior authorization process take in Illinois?
A: Standard reviews take 15-30 days. Expedited reviews for urgent medical situations are completed within 72 hours. Track your request through Humana's provider portal.

Q: What if Krystexxa isn't on my Humana formulary?
A: You can request a formulary exception by having your prescriber submit supporting documentation showing medical necessity and inadequate formulary alternatives.

Q: Can I get an expedited appeal if my gout is severe?
A: Yes, if delays would seriously jeopardize your health, request expedited review. Your prescriber must document the urgency and provide contact information for follow-up.

Q: Does step therapy apply if I failed these medications in another state?
A: Documentation of prior failures should transfer, but you may need to provide pharmacy records and clinical notes from your previous providers to verify adequate trials.

Q: What happens if Humana requests a peer-to-peer review?
A: Your prescriber will discuss the case directly with Humana's medical director before a denial is issued. This is your opportunity to address any clinical questions.

Q: How do I know if my G6PD test is normal?
A: Your lab report should show either "negative" for qualitative tests or values within the normal reference range for quantitative tests. G6PD deficiency is an absolute contraindication for Krystexxa.

Q: Can I appeal to an independent reviewer in Illinois?
A: Yes, Illinois guarantees external review rights. After your internal appeal is denied, you have 30 days to request independent review through the Illinois Department of Insurance.

Q: What if I can't afford the copay even with insurance?
A: Contact Amgen By Your Side (1-844-KRYSTEXXA) for financial assistance programs. Medicare patients should explore Extra Help and foundation grants since manufacturer copay cards aren't allowed.

Sources & Further Reading

Disclaimer: This guide provides educational information about insurance coverage processes and should not be considered medical or legal advice. Coverage decisions depend on individual circumstances, plan specifics, and clinical factors. Always consult with your healthcare provider about treatment options and work directly with your insurance plan for coverage determinations. For personalized assistance with appeals and prior authorizations, consider consulting with healthcare advocates or legal professionals specializing in insurance matters.

Powered by Counterforce Health—AI that turns drug denials into evidence-based appeals patients and clinicians can submit today.